Active Biotech AB

Type: Company
Name: Active Biotech AB
Nationality: Sweden
Web Address: http://activebiotech.com/
Fact Sheet: Fact Sheet for Active Biotech AB
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

Active Biotech schedules AGM

Active Biotech AB will hold its annual general meeting at Elite Hotel Ideon, Scheelev$¤gen 27 in Lund, Sweden, on 15 May at 5 p.m.Story provided by StockMarketWire.com ... [Published TrustNet - Apr 14 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 3 reports

Active Biotech – Notice of Annual General Meeting of Shareholders

The Board of Directors of Active Biotech AB (publ) has issued a notice to the Annual General Meeting, which is to take place at 5 p.m. on Thursday, May 15, 2014, at 5 pm at Elite Hotel Ideon, Scheelevägen 27 in Lund, Sweden.Please see the attached notification, ... [Published PR-Portal.com - Apr 14 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 7 reports

Global Multiple Sclerosis (MS) Therapeutics Market Report

PR NewswireDUBLIN April 11 2014DUBLIN April 11 2014 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/btp9ds/global_multiple) has announced the addition of the report to their offering.(Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... [Published PharmiWeb - Apr 11 2014]
First reported Apr 07 2014 - Updated Apr 08 2014 - 5 reports

Annual Report 2013 Active Biotech AB

(GLOBE NEWSWIRE) -- Active Biotech's Annual Report 2013 (in Swedish) is now available for download at www.activebiotech.com. The English version will be available within short. Help employers find you! Check out all the jobs and post your resume. ... [Published BioSpace - Apr 07 2014]
First reported Mar 31 2014 - Updated Mar 31 2014 - 1 reports

No preliminary investigation on Active Biotech

In the end of February Active Biotech was reported to the Swedish Economic Crime Authority, which has now decided not to precede with a preliminary investigation.The complaint to the Swedish Economic Crime Authority came from the organization INDEIN (Investigation ... [Published Nordic Life Science - Mar 31 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 1 reports

Evotec FY 2013: Execute on Innovate to Create Value

(GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN:DE0005664809) today announced its financial results for the fiscal year ended 31 December 2013, which are in line with the revised expectations communicated in the fourth quarter 2013.Strongest ... [Published Virtual Strategy Magazine - Mar 25 2014]
First reported Feb 27 2014 - Updated Feb 27 2014 - 1 reports

Multiple sclerosis drug in development: laquinimod

A new oral multiple sclerosis drug in development, Nerventra (laquinimod), appears to have modest effects on relapses but there is a possibility of long-term benefits, according to the newly-published results of the BRAVO trial (Vollmer and colleagues. ... [Published MSology - Feb 27 2014]
Entities: Laquinimod, Avonex, Placebo
First reported Feb 18 2014 - Updated Feb 18 2014 - 1 reports

Immunicum: Interim Report July - December 2013

Gothenburg, Sweden, 2014-02-18 08:59 CET (GLOBE NEWSWIRE) -- Second half of 2013 compared with the same period in 2012 The net loss for the period July 1 - December 31, 2013 amounted to - 5 583 KSEK, compared to - 2 177 KSEK for the same period in 2012. ... [Published GlobeNewswire - Feb 18 2014]
Entities: T-cells, Cancer, Kidney
First reported Jan 27 2014 - Updated Jan 28 2014 - 1 reports

Frontrunning: January 27

Emerging sell-off hits European shares, lifts yen ( Reuters ) - but not really if you hit refresh since the latest central bank bailout announcement Apple’s Holiday Results to Show Whether Growth Is Back ( BBG ) Israel attacked Syrian base in Latakia, ... [Published Zero Hedge - Jan 27 2014]
First reported Jan 27 2014 - Updated Jan 27 2014 - 1 reports

Teva and Active Biotech remain committed for development of Nerventra for multiple sclerosis

Teva Pharmaceutical Industries and Active Biotech have announced that both companies remain committed to the Nerventra (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment ... [Published Pharmaceutical Business Review - Jan 27 2014]
First reported Jan 24 2014 - Updated Jan 24 2014 - 1 reports

Handelsstopp i/Trading halt in Active Biotech AB (7/14)

Börsen har fattat beslut om att stoppa handeln för aktierna i Active Biotech AB (ACTI, ISIN-kod SE0001137985, orderboks ID 877) från klockan 13:10 tills vidare med hänvisning till 22 kap. 1§ p 1 lag (2007:528) om värdepappersmarknaden.Finansinspektionen ... [Published GlobeNewswire - Jan 24 2014]
First reported Nov 07 2013 - Updated Nov 07 2013 - 1 reports

Active Biotech AB Interim Report January - September 2013

Laquinimod* Analysis of data from the Phase III ALLEGRO study shows that laquinimodprovides a beneficial impact on brain tissue damage; Laquinimod-treatedpatients accumulated significantly less brain tissue damage caused byneurodegeneration* New data ... [Published GlobeNewswire - Nov 07 2013]

Quotes

Market Report, "Marina Biotech Inc. (Formerly MDRNA Inc.) - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report" , Published
More From BioPortfolio on "Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019"

More Content

All (65) | News (30) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (5) | Press Releases (28)
sort by: Date | Relevance
Active Biotech schedules AGM [Published TrustNet - Apr 14 2014]
Active Biotech - Notice of Annual General Meeti... [Published GlobeNewswire: Advertising News - Apr 14 2014]
Active Biotech - Notice of Annual General Meeti... [Published GlobeNewswire: Advertising News - Apr 14 2014]
Active Biotech – Notice of Annual General Meeti... [Published PR-Portal.com - Apr 14 2014]
Active Biotech : Active Biotech - Notice of Ann... [Published Investegate - Apr 14 2014]
Active Biotech - Notice of Annual General Meeti... [Published EuroInvestor - Apr 14 2014]
Global Multiple Sclerosis (MS) Therapeutics Mar... [Published PharmiWeb - Apr 11 2014]
Global Multiple Sclerosis (MS) Therapeutics Mar... [Published Rock Hill Herald - Apr 11 2014]
Global Multiple Sclerosis (MS) Therapeutics Mar... [Published Sacramento Bee - Apr 11 2014]
Global Multiple Sclerosis (MS) Therapeutics Mar... [Published TheStreet.com - Apr 11 2014]
Global Multiple Sclerosis (MS) Therapeutics Mar... [Published Yahoo! Finance - Apr 11 2014]
Global Multiple Sclerosis (MS) Therapeutics Mar... [Published OSIX News - Apr 11 2014]
Global Multiple Sclerosis (MS) Therapeutics Mar... [Published TickerTech.com - Apr 11 2014]
Annual Report 2013 Active Biotech AB [Published BioSpace - Apr 07 2014]
Annual Report 2013 Active Biotech AB publ [Published BioPortfolio - Apr 07 2014]
Annual Report 2013 Active Biotech AB (publ) [Published NASDAQ OMX - Apr 07 2014]
Annual Report 2013 Active Biotech AB (publ) [Published PR-Portal.com - Apr 07 2014]
Annual Report 2013 Active Biotech AB (publ) [Published GlobeNewswire: Advertising News - Apr 07 2014]
Annual Report 2013 Active Biotech AB (publ) [Published GlobeNewswire - Apr 07 2014]
No preliminary investigation on Active Biotech [Published Nordic Life Science - Mar 31 2014]
Market Report, "Marina Biotech, Inc. (Formerly ... [Published SBWire - Mar 26 2014]
Evotec FY 2013: Execute on Innovate to Create V... [Published Virtual Strategy Magazine - Mar 25 2014]
Multiple sclerosis drug in development: laquinimod [Published MSology - Feb 27 2014]
Change in the clinical development program for ... [Published GlobeNewswire: Acquisitions News - Feb 19 2014]
Change in the clinical development program for ... [Published GlobeNewswire: Acquisitions News - Feb 19 2014]
Immunicum: Interim Report July - December 2013 [Published GlobeNewswire - Feb 18 2014]
Active Biotech AB Year-end report January - Dec... [Published GlobeNewswire: Advertising News - Feb 13 2014]
Active Biotech AB Year-end report January - Dec... [Published GlobeNewswire: Advertising News - Feb 13 2014]
Frontrunning: January 27 [Published Zero Hedge - Jan 27 2014]
Teva and Active Biotech remain committed for de... [Published Pharmaceutical Business Review - Jan 27 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Multiple sclerosis drug in development: laquinimod [Published MSology - Feb 27 2014]
A new oral multiple sclerosis drug in development, Nerventra (laquinimod), appears to have modest effects on relapses but there is a possibility of long-term benefits, according to the newly-published results of the BRAVO trial (Vollmer and colleagues. ...
Frontrunning: January 27 [Published Zero Hedge - Jan 27 2014]
Emerging sell-off hits European shares, lifts yen ( Reuters ) - but not really if you hit refresh since the latest central bank bailout announcement Apple’s Holiday Results to Show Whether Growth Is Back ( BBG ) Israel attacked Syrian base in Latakia, ...
1

Press Releases

sort by: Date | Relevance
Active Biotech - Notice of Annual General Meeti... [Published GlobeNewswire: Advertising News - Apr 14 2014]
Active Biotech - Notice of Annual General Meeti... [Published GlobeNewswire: Advertising News - Apr 14 2014]
Annual Report 2013 Active Biotech AB (publ) [Published GlobeNewswire: Advertising News - Apr 07 2014]
Change in the clinical development program for ... [Published GlobeNewswire: Acquisitions News - Feb 19 2014]
Change in the clinical development program for ... [Published GlobeNewswire: Acquisitions News - Feb 19 2014]
1 2 3 4 5 6
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.